These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 1300551)

  • 21. Impact of erythropoietin on the dialysis prescription.
    Van Wyck DB
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):71-5. PubMed ID: 1928083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring erythropoietin therapy for anaemia of chronic renal failure by serum erythropoietin assays.
    Marsden JT; Sherwood RA; Hillis A; Peters TJ
    Ann Clin Biochem; 1993 Mar; 30 ( Pt 2)():205-6. PubMed ID: 8466156
    [No Abstract]   [Full Text] [Related]  

  • 23. Anemia of chronic renal failure: treatment with erythropoietin.
    Navarro M; Alonso A; Avilla JM; Espinosa L
    Child Nephrol Urol; 1991; 11(3):146-51. PubMed ID: 1777893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Arterial hypertension in patients with chronic kidney insufficiency in hemodialysis with erythropoietin].
    Martins Prata M; Teixeira de Sousa F; Barbas J; Vinhaś J; Marques da Costa A
    Rev Port Cardiol; 1990 Feb; 9(2):119-23. PubMed ID: 2346662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis.
    Acharya VN; Sinha DK; Almeida AF; Pathare AV
    J Assoc Physicians India; 1995 Aug; 43(8):539-42. PubMed ID: 8772973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Erythropoietin treatment in children with renal failure.
    Van Damme-Lombaerts R; Herman J
    Pediatr Nephrol; 1999 Feb; 13(2):148-52. PubMed ID: 10229005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum.
    Tsai JC; Lai YH; Tsai ZY; Chien LJ; Tsai JH
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Mar; 7(3):126-35. PubMed ID: 1865507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of anemia in patients with chronic renal insufficiency undergoing hemodialysis with recombinant human erythropoietin: 12 months' experience].
    de Sousa FT; Prata MM; Barbas JV; dos Santos JP
    Acta Med Port; 1990; 3(6):347-52. PubMed ID: 2089856
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of low-dose erythropoietin in predialysis chronic renal failure patients.
    Mitwalli A; Abuaisha H; al Wakeel J; al Mohaya S; Alam AA; el Gamal H; Fayed H
    Nephrol Dial Transplant; 1993; 8(10):1085-8. PubMed ID: 8272220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The effect of acetate-free biofiltration on anemia and use of erythropoietin].
    Eiselt J; Opatrný K; Sefrna F; Malánová L; Bouda M; Opatrný K
    Cas Lek Cesk; 1996 Aug; 135(16):525-9. PubMed ID: 8964066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and blood rheologic stability in erythropoietin-treated predialysis patients.
    Brown CD; Friedman EA
    Am J Nephrol; 1990; 10 Suppl 2():29-33. PubMed ID: 2260615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence for amelioration of endothelial cell dysfunction by erythropoietin therapy in predialysis patients.
    Kuriyama S; Hopp L; Yoshida H; Hikita M; Tomonari H; Hashimoto T; Sakai O
    Am J Hypertens; 1996 May; 9(5):426-31. PubMed ID: 8735172
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular effects of recombinant human erythropoietin in predialysis patients.
    Portolés J; Torralbo A; Martin P; Rodrigo J; Herrero JA; Barrientos A
    Am J Kidney Dis; 1997 Apr; 29(4):541-8. PubMed ID: 9100042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal risk-benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model - hypertension, anaemia, inflammation and drug dose.
    Ribeiro S; Garrido P; Fernandes J; Vala H; Rocha-Pereira P; Costa E; Belo L; Reis F; Santos-Silva A
    Clin Exp Pharmacol Physiol; 2016 Mar; 43(3):343-54. PubMed ID: 26889660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blood pressure response to erythropoietin injection in hemodialysis and predialysis patients.
    Miyashita K; Tojo A; Kimura K; Goto A; Omata M; Nishiyama K; Fujita T
    Hypertens Res; 2004 Feb; 27(2):79-84. PubMed ID: 15005270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hemodynamic and volume changes by recombinant human erythropoietin (rHuEPO) in the treatment of anemic hemodialysis patients.
    Hori K; Onoyama K; Iseki K; Fujimi S; Fujishima M
    Clin Nephrol; 1990 Jun; 33(6):293-8. PubMed ID: 2376091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erythropoietin and cardiovascular risk.
    Allegra V; Martimbianco L; Mengozzi G; Vasile A
    Blood Purif; 1995; 13(6):301-13. PubMed ID: 8821194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant human erythropoietin therapy in children on dialysis.
    Jabs K; Harmon WE
    Adv Ren Replace Ther; 1996 Jan; 3(1):24-36. PubMed ID: 8620365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of transfusion-dependent anaemia of chronic renal failure with recombinant human erythropoietin. A European multicentre study in 142 patients to define dose regimen and safety profile.
    Sundal E; Businger J; Kappeler A
    Nephrol Dial Transplant; 1991; 6(12):955-65. PubMed ID: 1798595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.